SCHEMBL13675548

SCHEMBL13675548

O=C1NCCC1Cc1c(O)cccc1Cl

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.41
KMT2A Q03164 2/20 0.37
MEN1 O00255 1/20 0.35
RAB9A P51151 1/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
POLB P06746 1/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
CYP3A4 P08684 1/20 0.34
CYP2C19 P33261 1/20 0.34
TAAR1 Q96RJ0 1/20 0.34
COMT P21964 2/20 0.34
TSHR P16473 1/20 0.33
OPRL1 P41146 1/20 0.33
HSD17B10 Q99714 1/20 0.33
PDCD1 Q15116 1/20 0.33
CD274 Q9NZQ7 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14365029 0.90 KMT2A (0.38) LMNAKMT2AMEN1RAB9AL3MBTL1
SCHEMBL4519254 0.81 GLA (0.38) LMNAKMT2AMEN1RAB9AL3MBTL1
SCHEMBL13675555 0.80 PDCD1 (0.40) LMNAPDCD1CD274
SCHEMBL14365225 0.77 DCPS (0.38) POLBOPRL1PDCD1CD274
SCHEMBL13675547 0.74 TAAR1 (0.38) KMT2AMEN1ALDH1A1TAAR1HSD17B10
SCHEMBL12290783 0.73 TSHR (0.43) LMNAKMT2AMEN1RAB9AL3MBTL1
SCHEMBL3002320 0.69 HSD11B1 (0.57) LMNAKMT2AMEN1POLBALDH1A1
SCHEMBL31021674 0.69 KDM4E (0.41) L3MBTL1POLBKDM4EALDH1A1TSHR
SCHEMBL837901 0.68 DDB1 (0.60) KMT2ARAB9APOLBALDH1A1
SCHEMBL2991612 0.68 HSD11B1 (0.44) LMNAKMT2AMEN1POLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
EP-1864971-A1 PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES Takeda Pharmaceutical Company Limited (JP) 2007-12-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes HSD11B1, HSD17B1, HSD11B2 LMNA 2846/4885KMT2A 2379/4885MEN1 1254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.